Sanofi's paediatric hexavalent vaccine approved by U.S. FDA

赛诺菲与默克公司合作开发儿科6价疫苗 Vaxelis 获得美国 FDA 批准

2018-12-27 17:16:38 YAHOO!FINANCE

本文共222个字,阅读需1分钟

The U.S. Food and Drug Administration approved Sanofi's new paediatric vaccine immunizing children against six diseases, the French pharmaceutical lab said on Wednesday. Sanofi developed the new vaccine, dubbed Vaxelis, in partnership with Merck. Vaxelis is designed for children aged 6 weeks to 4 years old and is designed to keep them from contracting diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to haemophilus influenzae type B. Sanofi and Merck are now working on the production and supply of Vaxelis aiming to make it available on the market in 2020 or later.
法国药物实验室周三表示,美国食品和药物管理局( FDA )批准了赛诺菲( Sanofi )针对6种疾病的儿童免疫疫苗. 赛诺菲与默克公司合作开发了名为 Vaxelis 的新型疫苗。 Vaxelis 专为6周至4岁的儿童设计,旨在防止他们感染白喉、破伤风、百日咳、小儿麻痹症、乙肝和 B 型血友病所致的侵袭性疾病。 赛诺菲( Sanofi )和默克( Merck )目前正致力于生产和供应 Vaxelis ,目标是在2020年或以后在市场上销售。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文